STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

PRME Schedule 13G filing by T. Rowe Price Investment Management

T. Rowe Price Investment Management reported beneficial ownership of 9.2M shares, representing 12% of Prime Medicine, Inc. in this filing.

FiledNov 14, 2025
Ownership dateSep 30, 2025
Reported shares9.2M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 9.2M
Shared voting power 9.2M
Sole dispositive power 9.2M
Shared dispositive power 9.2M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$3.37as of Nov 14, 2025
Latest tracked price$3.08as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
T. Rowe Price Investment Management
CIK
CIK0001897612
Accession
0001897612-25-000555
Form
Schedule 13G
Open SEC filing View PRME ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →